H. Lundbeck A/S (HLUN-B.CO)

DKK 41.16

(0.88%)

Market Cap (In DKK)

32.65 Billion

Revenue (In DKK)

19.91 Billion

Net Income (In DKK)

2.29 Billion

Avg. Volume

561.52 Thousand

Currency
DKK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
31.62-49.38
PE
-
EPS
-
Beta Value
0.18
ISIN
DK0061804770
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Charl van Zyl
Employee Count
-
Website
https://www.lundbeck.com
Ipo Date
2022-06-10
Details
H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.